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Abstract
Coronary heart disease is the principal cause of death in the industrialized world. Its most serious expression, acu-
te myocardial infarction, causes 7.2 million deaths each year worldwide, and it is estimated that 20% of all people 
will suffer heart failure in the course of their lifetime. The control of risk cardiovascular factors, including arterial 
hypertension, obesity and diabetes mellitus is the best way to prevent such diseases. The most frequent and serious 
cardiovascular emergencies that can manifest during dental treatment are chest pain (as a symptom of underlying 
disease) and acute lung edema. Due to the high prevalence and seriousness of these problems, the dental surgeon 
must be aware of them and should be able to act quickly and effectively in the case of an acute cardiovascular event. 
In patients with a history of cardiovascular disease, attention must center on the control of pain, the reduction of 
stress, and the use or avoidance of a vasoconstrictor in dental anesthesia. In turn, caution is required in relation to 
the antiplatelet, anticoagulant and antihypertensive medication typically used by such patients.
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Introduction
The motor of cardiac activity is the myocardium, com-
posed of contractile striated muscle fibers that exert the 
pumping action of  the heart. Anatomically, the latter 
comprises two atria and two ventricles. Physiologically, 
the heart can be divided into two halves: the right heart 
receives systemic venous blood from the upper and lower 
vena cavas, and redistributes it towards the pulmonary 
circuit through the pulmonary arteries. In turn, the left 
heart drains oxygenated arterial blood from the pulmo-
nary veins and redirects it to the rest of the body (systemic 
circulation) through the aorta. This blood trajectory and 
distribution is possible thanks to the cardiac cycle. The 
epicardial and intramyocardial coronary arteries supply 
the myocardium with the necessary oxygen and nutrients. 
A reduction in blood flow through these arteries is respon-
sible for ischemic heart disease (1)(Figure 1).
The electrical activity of the heart originates in the sinoa-
trial (SA) node, which is composed of numerous pace-
maker cells. Conduction continues along the internodal 
interatrial bundles to the atrioventricular (AV) node, and 
then to the bundle of His where the conduction system 
ramifies towards both ventricles via the so-called Purkinje 
fibers. Each electrical impulse traveling this circuit gene-
rates one harmonious contraction of the heart. Under 
normal resting conditions, the number of cycles completed 
per minute is between 60-100. The electrical field generated 
by such conduction activity can be recorded by means of 
the electrocardiogram (ECG).
According to the World Health Organization (WHO), in 
the year 2003, cardiovascular diseases caused a total of 
16.7 million deaths. Of these, 7.2 million corresponded 
to ischemic heart disease, 5.5 million to cerebrovascular 
accidents (stroke), and 3.9 million to other cardiovascular 
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disorders - fundamentally associated to arterial hyperten-
sion (2).
The present study provides a review of  the two most 
frequent cardiovascular disorders - ischemic disease and 
heart failure - and discusses the approach to be adopted 
by the dental surgeon when dealing with patients that 
suffer such problems.
1. Ischemic heart disease
Myocardial ischemia occurs as a result of  diminished 
coronary blood flow. Such reduction in flow can be 
partial or total, and is usually attributable to thrombus 
formation over an atheroma plaque, with occlusion of 
the coronary vascular lumen. The presence of atheroma 
plaques (arteriosclerosis) within the coronary arteries is 
the most common cause of  myocardial ischemia (over 
90% of all cases). When the plaque ruptures, ulcerates or 
suffers fissures, primary platelet aggregation takes place. 
This effect in turn is reinforced by the intervention of 
agonists (collagen, ADP, serotonin, adrenalin) - leading 
to the release and production of thromboxane A2, which 
is responsible for local vasoconstriction (among other 
actions). The tissue factor exposed to the bloodstream as 
a result of vascular endothelial damage triggers hemos-
tasia and blood coagulation - the end result of which is 
the accumulation of platelets and fibrin that conform a 
thrombus (3).
Ischemic heart disease has two manifestations according 
to the degree of arterial vascular obliteration and the pre-
sence or absence of myocardial necrosis. When obliteration 
is total (full occlusion) and tissue necrosis occurs, acute 
myocardial infarction (AMI) results. In the case of partial 
obliteration of the vascular lumen without myocardial 
necrosis, angina (chest pain) results (4). The differences 
between these two conditions are reflected in Table 1. 
However, it is sometimes difficult to differentiate between 
AMI and angina in the early stages of the process. As a 
result, these manifestations are presently classified as acute 
coronary syndrome (ACS) with ST-segment elevation on 
the electrocardiogram (which can benefit from emergency 
myocardial reperfusion treatment) and ACS without ST-
segment elevation (where the objective is to stabilize the 
complicated atheroma plaque)(5).
Chest pain is the initial presentation in approximately 45% 
of cases, with myocardial infarction in 42%, and sudden 
death in the remaining 13%. 
- Acute myocardial infarction (AMI)
Acute myocardial infarction is characterized by acute-
onset myocardial necrosis of ischemic origin, secondary 
to thrombotic occlusion of a coronary artery (6).
Ischemic heart disease is principal cause of  death in 
industrialized countries. In Spain, the incidence is 
135-210 infarctions/100,000 males/year, versus 29-61 
infarctions/100,000 females/year (7). Despite the diffe-
rence in incidence between males and females, the latter 
have a comparatively greater risk of death over the short 
and long term following AMI. This is because infarction 
in women typically occurs at later ages, and moreover, 
Fig. 1. Arteriographic view of the coronary arteries. The arrows 
indicate points of stenosis.
Infarction Angina
Degree of ischemia Complete Partial
Cell necrosis Yes No
Subsides with rest, 
sublingual nitroglycerin
No Yes




Presence or absence of 
ST-segment alterations
Table 1. Differences between acute myocardial infarction and chest pain (angina, angor 
pectoris).
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the causes and locations of infarction are different. The 
co-morbidity characteristics found in women are an 
additional influencing factor (8). In the United States it 
is estimated that 500,000 people suffer myocardial infarc-
tion each year (4). The mortality is maximum in the first 
hours after the event, and approximately 50% die before 
reaching hospital (3).
The cardiovascular risk factors found among the general 
population have been well known for decades: smoking, 
arterial hypertension, hyperlipidemia, diabetes mellitus, 
age, the male sex and genetic factors have all been impli-
cated (9).
Arterial hypertension (AHT) affects 6-8% of the general 
population. The underlying cause is known in 1-15% of 
cases (secondary hypertension); consequently, in the great 
majority of  subjects the cause of  hypertension is not 
known (primary, essential or idiopathic hypertension). The 
condition remains asymptomatic for a prolonged period 
of time, and subsequently evolves towards arteriosclerosis 
that ultimately leads to the cardiac problems examined 
in the present study (among other disorders). In effect, 
the presence of arterial hypertension implies a three-fold 
increase in the incidence of coronary disease.
Diabetes mellitus (DM) is a very common disease that affects 
about 5% of the population in industrialized countries - with 
important geographical variations. It is a metabolic disorder 
produced by insulin deficiency in which the affected indivi-
dual is unable to adequately metabolize carbohydrates. Two 
types of diabetes can be observed: type I (typical of younger 
individuals, with a sudden onset and a tendency to produce 
ketoacidosis), and type II (more common in adults, with a 
slow onset and no tendency to produce ketoacidosis). Its 
complications include diabetic macroangiopathy, which is a 
form of arteriosclerosis characterized by faster progression 
than in the general population. It is the most frequent cause 
of death among diabetics. In effect, 49% of all deaths among 
diabetics in the 35-44 years age range are due to acute myo-
cardial infarction (10).
Clinically, AMI manifests as acute, intense and oppressive 
pain of retrosternal or precordial location, and sometimes 
irradiating to the arms, neck, mandible or back. The pain 
lasts for over half an hour and does not subside with rest. In 
addition, it is accompanied by profuse perspiration, nausea 
and vomiting, and the patient typically experiences a sensa-
tion of imminent death. AMI can also manifest as a sudden 
loss of consciousness, confusional state or weakness.
The triggering stimuli are emotional stress, intense 
physical exercise, some background disease, or surgical 
intervention. Silent infarctions, i.e., those without pain, 
are more common among elderly individuals, in women, 
and in diabetic patients. It should be mentioned that other 
processes such as pulmonary thromboembolism, aortic 
dissection, pneumothorax, costochondrosis or simple 
episodes of a psychic nature can manifest with pain of 
similar characteristics (3,4).
The diagnosis of AMI is based on the clinical findings, the 
ECG tracing and the determination of myocardial necrosis 
markers (11). The ECG reflects the impact of sudden and 
acute ischemia upon the electrical activity of the heart, in 
the form of ST-segment elevation (Figure 2). 
The appearance of pathological Q-waves is synonymous of 
myocardial necrosis. The determination of serum markers 
has grown in importance and diagnostic usefulness over 
the years. In this context, evaluations are made of serum 
creatine phosphokinase and its isoform MB (CPK and 
CPK-MB), troponin T and I, and myoglobin. Troponin I 
has displaced CPK-MB in terms of relevance (12). Other 
complementary diagnostic techniques are chest X-rays, 
two-dimensional (2D) echocardiography, gammagraphy 
and cardiac catheterization.
The objective of  in-hospital treatment in acute phase 
AMI is to ensure immediate myocardial reperfusion (13), 
based on pharmacological or surgical means. Fibrinoly-
sis plays a particularly important role in the first hours 
after infarction. Its principal complication (from which 
the contraindications of such therapy are derived) is the 
appearance of bleeding. A possible option in this sense 
is to add aspirin as coadjuvant treatment, at a dose of 
75-325 mg/day (14), thanks to its antiplatelet action, and 
heparin. Other drugs used for the treatment and secon-
dary prevention of AMI comprise beta-blockers (which 
reduce oxygen consumption and cardiac cycle frequency 
and contractility), calcium antagonists, and angiotensin 
converting enzyme inhibitors (ACEIs).
The complications that may manifest after AMI can be 
divided into three categories: mechanical, electrical and 
ischemic. The most important complication in terms of 
frequency and severity is heart failure, followed by atrial or 
ventricular fibrillation, conduction block, postinfarction 
angina and reinfarction.
Fig. 2. ECG tracing of a patient with acute myocardial infarction. The 
arrows indicate ST-segment elevation.
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- Angor pectoris – chest pain
 Angor pectoris, angina or chest pain is the result of a 
partial and reversible reduction in myocardial perfusion, 
of thrombotic origin, in which no cell necrosis occurs. 
Stable angina is preceded by physical exertion or emotional 
stress, and is characterized by pain of the same location 
and characteristics as pain in AMI, though of lesser du-
ration (in the order of minutes). It also subsides with rest 
and/or with the administration of sublingual nitroglyce-
rin. In contrast, unstable angina manifests under resting 
conditions, the pain is characteristically longer lasting and 
more intense (though without exceeding 20-30 minutes), 
and is less responsive to nitrates. In one-half  of all cases 
of angina the ECG tracing is normal, while in the rest of 
cases ST-segment alterations are evidenced. Stable angina 
can evolve towards unstable angina, or the latter may lead 
to AMI or (in the worst of cases) to sudden death. Patients 
with a history of chest pain receive treatment in the form 
of antiplatelet drugs (aspirin, ticlopidine, clopidogrel), 
nitrates (nitroglycerin), beta-blockers and calcium anta-
gonists - a condition that must be taken into account by 
the dental surgeon, as will be seen below.
Approach of the dental surgeon to emergency situations
In the event of chest pain with the above mentioned charac-
teristics, location and triggering stimuli inherent to ischemic 
episodes, the approach is the same regardless of whether 
angina or AMI is involved. The associated presence of 
dyspnea, syncope, hypotension, intense hypertension or 
tachyarrhythmia suggests a potentially fatal disorder. The 
emergency service therefore must be contacted immediately 
(telephone number 112), and the patient should be administe-
red oxygen with a mask or nasal cannula at a rate of 4-6 liters/
minute. This is to be followed by sublingual nitroglycerin 
tablets (or using an aerosol formulation) at a dose of 0.4 - 0.8 
mg. Dosing can be repeated every five minutes. The patient 
should be instructed to bite the tablet and place it under the 
tongue. The effect should be noted after approximately two 
minutes, and the dose is to be repeated every 10 minutes up 
to 3-4 times if improvement is not obtained. It should be 
taken into account that the administration of nitroglycerin 
can cause side effects with some frequency, in the form of 
headache, dizziness and tachycardia (15). It is also possible to 
administer 325 mg of aspirin, in view of its antiplatelet effects, 
though taking into account that the drug also increases the 
blood levels of nitroglycerin, and therefore can increase 
the toxicity of the latter. The administration of aspirin in 
the first hours following infarction reduces mortality 20%. 
Consequently, as soon as infarction is suspected, a dose of 
aspirin is recommended. If the pain persists for more than 20 
minutes, fails to subside with rest, and does not respond to 
three doses of sublingual nitroglycerin, the diagnosis is very 
likely AMI. In this case, emergency care must center on the 
provision of pain relief as quickly as possible, administering 
morphine in fractionated doses of 5 mg via the intramuscular 
or intravenous route (½ ampoule of generic formulation 
containing 1 ml of 1% solution). The dose can be increased 
to 30 mg in the first 20 minutes, or alternatively pentazocine 
can be provided at equivalent doses if the patient presents 
background lung disease (½ ampoule containing 30 mg via 
the intramuscular or intravenous route every 5 minutes). 
Sedation is to be provided with oral benzodiazepine in the 
event of vegetative manifestations, with the application of 
cardiopulmonary resuscitation maneuvers where required 
(16)(Figure 3).
Fig. 3. Approach to chest pain of possible ischemic origin.
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2. Heart failure
Heart failure comprises the global clinical manifestations 
associated with ventricular dysfunction, heart valve defects 
or ventricle loading conditions, reflected as a reduction in 
cardiac output (volume pumped per minute) and deficient 
tissue distribution. In 2003, in Spain, heart failure caused 
20,000 deaths out of a total of 385,000 cases (i.e., a 5.2% 
mortality rate), and accounted for 15.3% of all deaths 
of cardiovascular origin. It is estimated that 20% of all 
people will suffer heart failure in the course of their life-
time (17). The survival of these patients is limited due to 
the intervention of aggravating factors and the presence 
of concomitant diseases.
Ventricle function is regulated by four factors: myocardial 
contractility, ventricular preloading and postloading, and 
heart rate. Ventricular postload is the most relevant para-
meter, as it reflects the strength of myocardial contraction, 
and is the principal determinant of ejection volume. When 
any one of these four factors fails, the heart becomes unable 
to supply the required blood flow in relation to the existing 
venous return flow and the tissue and organ needs.
Failure can be acute, as a result of exposure to cardiotoxic 
drugs or secondary to coronary occlusion, or it may be 
chronic and associated to a patient history of arterial hy-
pertension and ischemic heart disease. The chronic form of 
heart failure is the most common presentation, and is the 
form referred to below. As has already been mentioned, the 
principal cause is coronary disease. Over 45% of all cases 
of AMI are complicated by heart failure (18). Other causes 
are dilated myocardiopathy, valve disease, alcoholic heart 
disease, cor pulmonale and hypertrophic and restrictive 
cardiomyopathy. Arterial hypertension is considered to be 
the most important risk factor, particularly when conco-
mitant to coronary atherosclerosis. Another factor to be 
taken into account is diabetes mellitus, which increases the 
risk of chronic heart failure 2.5-5 times, due to the known 
metabolic alterations and increased cellular oxidative 
stress levels involved (19). Chronic heart failure, resulting 
from deficient left ventricle function, is characterized 
by lung congestion (clinically manifesting as important 
dyspnea, cough, hemoptysis and nocturia) and tissue 
hypoperfusion (manifesting as asthenia, muscle weakness, 
palpitations, lessened tolerance of physical exercise, men-
tal alterations and oliguria). In the case of right ventricle 
failure, the resulting manifestations comprise peripheral 
venous congestion with the appearance of ankle and foot 
edemas, with a positive fovea sign.
Surgical management is based on heart transplantation. 
Due to the complexity of the condition, other techniques 
have also been developed, such as mitral valve replacement 
or repair, left ventricle reconstruction, total or partial me-
chanical replacement of the ventricle, the implantation of a 
pacemaker, cardiomyoplasty, or coronary revascularization 
(20). Pharmacological treatment centers on neurohormonal 
block with ACEIs (captopril, enalapril, lisinopril) and beta-
blockers (atenolol, bisoprolol, propanolol); aldosterone 
antagonists (spironolactone) and angiotensin receptor 
antagonists are also used (losartan, valsartan)(21). 
Acute heart failure, either primary or as an exacerbation 
of the chronic form of the disease, tends to manifest as 
acute lung edema. The most frequent triggering factors are 
severe and prolonged arterial hypertension, valve disease, 
ischemic heart disease (AMI) and severe pericardial disor-
ders. Lung edema is characterized by the displacement of 
liquid from the capillary space into the interstitial and al-
veolar compartments when pulmonary capillary pressure 
exceeds the oncotic pressure of plasma. Affected patients 
often present some background disorder or a history of 
progressive dyspnea, dry cough, asthenia, etc. Edema ma-
nifests with sudden onset or progressive dyspnea, cough 
with abundant pink colored expectoration, and a worsened 
general condition involving cyanosis, cold skin, intense 
perspiration and a sensation of extreme illness. The patient 
experiences suffocation and laryngeal irritation, and tends 
to adopt the sitting position to facilitate breathing. The 
condition may simulate an asthma episode. The clinical 
history of the patient and the absence of rales in asthma 
help to establish the differential diagnosis (Figure 4).
- Approach of the dental surgeon to acute lung edema
After contacting the emergency service (telephone number 
112), the patient is to be seated with the legs relaxed, and 
oxygen is to be administered by means of a mask or nasal 
catheter or cannula (4-6 liters/minute). Sublingual nitrogly-
cerin can be provided (0.4-0.8 mg), with repetition of the 
dose every 5 or 10 minutes if  blood pressure is maintained. 
The administration of  intravenous morphine (5 mg in 
an initial dose, followed by 1-2 mg every 5 minutes for a 
maximum of 15-20 mg in 30 minutes) helps reduce rest-
lessness, heart and breathing rate, and blood pressure (i.e., 
cardiorespiratory function is globally improved). However, 
due to the risk of respiratory depression in patients with 
Fig. 4. Chest X-ray view of a patient with acute lung edema.
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prior lung disease, the use of such medication requires 
extreme caution in patients of this kind, and morphine 
antagonists must be available in case morphine reversion 
proves necessary. In such situations, an initial intravenous 
dose of 0.4-2 mg is to be administered, repeating the dose 
every 2-3 minutes - without exceeding 10 mg. If  possible 
peripheral catheterization should be carried out to admi-
nister loop diuretics (furosemide 40-100 mg iv)(22,23).
3. Considerations applicable to dental practice
In patients with cardiovascular disease it is advisable to 
minimize the stress of visiting the dentist, and to provide 
effective pain treatment. The controversy as to whether 
or not to use a vasoconstrictor (adrenalin or levonor-
dephrine) with the local anesthetic solution is due to the 
effect of the former upon arterial pressure. In patients 
with heart disease it is common to use beta-blockers as 
antiarrhythmic and antihypertensive medication. Some 
of these drugs are non-selective, inhibiting both beta-1 
and beta-2 adrenergic receptors (propanolol, nadolol, 
timolol, pindolol), as a result of which they lower heart 
rate and cardiac output, and moreover exert a marked 
hypotensive effect - although vascular beta-2 adrenergic 
block facilitates the predominance of alpha-1 adrenergic 
tone in certain territories, with an increase in peripheral 
resistance and therefore of diastolic blood pressure. On 
the other hand, selective beta-blockers with alpha-1 anta-
gonistic action avoid this problem of increased peripheral 
vascular resistance (labetalol (Trandate®), carvedilol 
(as generic formulations, Coropres®)). Cardioselective 
beta-blockers preferentially exert their effects upon the 
beta-1 adrenergic receptors (metoprolol (Beloken®), 
atenolol (as generic formulations, Blokium®), esmolol 
(Brevibloc®)), reducing heart rate, conduction velocity 
in the atrioventricular node, and cardiac output (15 The 
joint administration of adrenalin, which acts mainly upon 
the beta-2 adrenergic receptors, can give rise to arterial 
hypertension and bradycardia - this being more likely to 
happen with non-cardioselective beta-blockers, by inter-
fering with their action upon these receptors. Moreover, 
it must be taken into account that beta-blockers can delay 
peripheral plasma clearance of the local anesthetic, and 
that the prolonged use of nonsteroidal antiinflammatory 
drugs (NSAIDs) can reduce the antihypertensive effects.
A visit to the dentist generates anxiety in itself, with the 
release of endogenous catecholamines in amounts that 
may exceed those administered with the local anesthetic 
solution. The association of a vasoconstrictor therefore 
should be limited, taking care not to exceed 0.04 mg of 
adrenalin (i.e., 2 carpules containing 1.8 ml of anesthetic 
with adrenalin 1:100,000). The use of retraction thread 
with adrenalin is not advised (24). 
During the first 6 months after AMI, dental treatment 
should be reserved for emergency situations destined to 
provide odontogenic pain relief: tooth extractions, the dra-
inage of abscesses, and pulpectomies - preferably carried 
out in the hospital setting. After this period of caution, 
treatment decision is conditioned by the individual situa-
tion and medical condition of the patient (25).
 Pharmacologically, special mention should be made of 
the antiplatelet drugs (aspirin, clopidogrel, ticlopidine, 
dipyridamole), the anticoagulants (antivitamin K or the 
coumarins), and the beta-blockers (already commented 
above). The interruption of  thrombolytic medication 
for the provision of dental treatment is risky, due to the 
possibility of  repeat thrombosis. If  the suspension of 
thrombolytic medication proves necessary, the decision to 
provide dental treatment must be taken in coordination 
with the physician supervising the patient medication 
(Table 2)(26,27). When antiplatelet medication cannot 
































Table 2. Antiplatelet and anticoagulant drugs commonly used in cardiovascular disease.
E302
Med Oral Patol Oral Cir Bucal. 2008 May1;13(5):E296-302.                                                                                                                                                                                          Cardiovascular-Dentistry                                                                         Med Oral Patol Oral Cir Bucal.  2008 May1;13(5):E296-302.                                                                                                                                                                                            Cardiovascular-Dentistry
be interrupted on occasion of invasive dental treatment, 
and a risk of  bleeding is anticipated, local hemostatic 
measures must be applied such as bone wax, sutures, ge-
latin of animal origin (Gelfoam®), regenerated oxidized 
cellulose (Surgicel®), collagen, plasma rich in platelets, 
thrombin (Thrombostat®), fibrin sealants (Tissucol®), 
and the use of an electric or laser scalpel (28). The use of 
antifibrinolytic agents is also advised, such as tranexamic 
acid (Amchafibrin®) or epsilon-aminocaproic acid (Ca-
proamin®). The intravenous route is not usually used in 
dental practice; rather, the oral route is employed: epsilon-
aminocaproic acid as a dose of 4 grams (1 ampoule) every 
4 or 6 hours, and tranexamic acid 1-1.5 g 2-3 times a day 
in tablets or ampoules (15). Tranexamic acid is also used 
in mouthrinse format.
In the case of anticoagulated patients, it is essential to de-
termine the INR (International Normalized Ratio) before 
invasive dental treatment, and without the need to inte-
rrupt the medication. The INR compares the prothrombin 
time (PT) of the patient versus a control or standard PT 
adjusted according to the International Sensitivity Index 
(ISI). It is accepted that oral surgical procedures are to 
be carried out with an INR of ≤ 4 (Table 2), applying the 
aforementioned hemostatic measures (29).
In patients carrying a pacemaker, interferences may occur 
with the use of pulpmeters, ultrasound for supragingival 
tartar removal, and the electrical scalpel (22). 
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